Emyria receives $1,162,000 R&D Tax Incentive Refund
Filed with ASX · · 2 pages · English
Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and care delivery company, is pleased to announce that it has received a Research and Development (R&D) Tax Incentive refund of $1,162,134 for the financial year 2020/2021. Emyria Managing Director Dr Michael Winlosaid: “Combined with the recent strategic investment from Tattarang, this R&D tax incentive refund streng
Earlier from Emyria
- Emyria Welcomes Tattarang as Strategic Investor
- MDMA Analogue Development Milestone
- Emyria selected to join Palantirs Foundry Builders Program
- Novel MDMA Analogue Screening Program Advanced
- Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
Later from Emyria
- Positive initial MDMA-analogue screening results
- Positive animal data for Emyrias ultra-pure CBD capsule
- Pause in Trading
- Emyria adds wearables to psychedelic-assisted therapy trials
- Notification regarding unquoted securities - EMD
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria